Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid

Pharmacogenomics

Volumn 13, Issue 9, 2012, Pages 1055-1071

  Chatzistefanidis, Dimitrios ^a   Georgiou, Ioannis ^a   Kyritsis, Athanassios P ^a   Markoula, Sofia ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

glucuronidation; metabolism; polymorphisms; UGT1A3; UGT1A4; UGT1A6; UGT1A9; UGT2B7; UGTs; valproic acid

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; VALPROIC ACID;

DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; EXON; GENE; GENE EXPRESSION; GENE LOCUS; GLUCURONOSYLTRANSFERASE 1A3 GENE; GLUCURONOSYLTRANSFERASE 1A4 GENE; GLUCURONOSYLTRANSFERASE 1A6 GENE; GLUCURONOSYLTRANSFERASE 1A9 GENE; GLUCURONOSYLTRANSFERASE 2B7 GENE; HAPLOTYPE; HUMAN; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; VALPROIC ACID;

EID: 84864418001     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.78     Document Type: Review

References (87)

1. Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie 18, 435-438 (1963).
2. Kukino K, Mineura K, Deguchi T, Ishii A, Takahira H. Studies on a new anticonvulsant drug, sodium dipropylacetate. Assay for metabolites and metabolic pathway. Yakugaku Zasshi. 92(7), 896-900 (1972) .
3. Kuhara T, Matsumoto I. Metabolism of branched medium chain length fatty acid. I. Omega-oxidation of sodium dipropylacetate in rats. Biomed. Mass. Spectrom. 1(4), 291-294 (1974).
4. Matsumoto I, Kuhara T, Yoshino M. Metabolism of branched medium chain length fatty acid. II. beta-oxidation of sodium dipropylacetate in rats. Biomed. Mass. Spectrom. 3(5), 235-240 (1976).
5. Kochen W, Imbeck H, Jakobs C. Studies on the urinary excretion of metabolites of valproic acid (dipropylacetic acid) in rats and humans. Arzneimittelforschung 27(5), 1090-1099 (1977).
6. Schäfer H, Lührs R. Metabolite pattern of valproic acid. Part I: gaschromatographic determination of the valproic acid metabolite artifacts, heptanone-3, 4-and 5-hydroxyvalproic acid lactone. Arzneimittelforschung. 28(4), 657-662 (1978).
7. Wong H, Kumar S, Rurak DW, Kwan E, Abbott FS, Riggs KW. Ontogeny of valproic acid disposition and metabolism: a developmental study in postnatal lambs and adult sheep. Drug Metab. Dispos. 28(8), 912-919 (2000).
8. Kumar S, Wong H, Yeung SA, Riggs KW, Abbott FS, Rurak DW. Disposition of valproic acid in maternal fetal, and newborn sheep. II: metabolism and renal elimination. Drug Metab. Dispos. 28(7), 857-864 (2000).
9. Ionescu C, Caira MR. Pathways of biotransformation-phase II reactions. In: Drug Metabolism: Current Concepts. Springer, Dodrecht, The Netherlands, 129-134 (2005).
10. Chen ZJ, Wang XD, Wang HS et al. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy. Seizure 21(2), 110-117 (2012).
11. Ritter JK, Chen F, Sheen YY et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem. 267(5), 3257-3261 (1992).
12. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J. Biol. Chem. 266(2), 1043-1047 (1991).
13. Harding D, Fournel-Gigleux S, Jackson MR, Burchell B. Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc. Natl Acad. Sci. USA 85(22), 8381-8385 (1988).
14. Gong QH, Cho JW, Huang T et al. Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11(4), 357-368 (2001).
15. Mackenzie PI, Bock KW, Burchell B et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15(10), 677-685 (2005).
16. Riedy M, Wang JY, Miller AP, Buckler A, Hall J, Guida M. Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics 10, 251-260 (2000).
17. Soars MG, Smith DJ, Riley RJ, Burchell B. Cloning and characterization of a canine UDP-glucuronosyltransferase. Arch. Biochem. Biophys. 391(2), 218-224 (2001).
18. Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyl transferases of the UGT1 gene family. Drug Metab. Dispos. 20(1), 50-55 (1993).
19. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid containing drugs. J. Pharm. Exp. Ther. 264(1), 475-479 (1993).
20. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch. Biochem. Biophys. 424(2), 219-225 (2004).
21. Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltranseferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos. 37(1), 229-236 (2009).
22. Izukawa T, Nakajima M, Fujiwara R et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab. Dispos. 37(8), 1759-1768 (2009).
23. Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-lucuronosyltransferases 1A8 and 1A10. Drug Metab. Dispos. 27(10), 1165-1170 (1999).
24. Krishnaswamy S, Duan SX, von Moltke LL, Greenblatt DJ, Court MH. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab. Dispos. 31(1), 133-139 (2003).
25. Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14(8), 487-499 (2004).
26. Xing Y, Yang L, Wang L et al. Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. Pharmacogenomics 10(5), 741-752 (2009).
27. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7(6), 485-495 (1997).
28. Peters WH, te Morsche RH, Roelofs HM. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J. Hepatol. 38(1), 3-8 (2003).
29. Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J. Pharmacol. Exp. Ther. 313(3), 1331-1339 (2005).
30. Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther. 313(3), 1340-1346 (2005).
31. Sun YP, Tan L, Wang Y, Song JH. Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate. Zhonghua Yi Xue Za Zhi 87(29), 2033-2035 (2007).
32. Wang Y, Gao L, Liu YP, Huang NN, Xu SJ, Ma DJ. Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan. Zhongguo. Dang Dai. Er. Ke. Za. Zhi. 12(6), 429-432 (2010).
33. Chu XM, Zhang LF, Wang GJ, Zhang SN, Zhou JH, Hao HP. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur. J. Clin. Pharmacol. doi:10.1007/s00228-012-1277- 7 (2012) (Epub ahead of print).
34. Hung CC, Ho JL, Chang WL et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 12(8), 1107-1117 (2011).
35. Guo Y, Hu C, He X, Qiu F, Zhao L. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab. Pharmacokinet. doi:10.2133/dmpk. DMPK-11-RG-144 (2012) (Epub ahead of print).
36. Saeki M, Saito Y, Jinno H et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab. Pharmacokinet. 20(1), 85-90 (2005).
37. Burchell B, Brierley CH, Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 57(20), 1819-1831 (1995).
38. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26(1), 73-77 (1998).
39. Bhasker CR, McKinnon W, Stone A et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8), 679-685 (2000).
40. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem. Pharmacol. 65(9), 1441-1449 (2003).
41. Chung JY, Cho JY, Yu KS et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther. 83(4), 595-600 (2008).
42. Holthe M, Rakvåg TN, Klepstad P et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3(1), 17-26 (2003).
43. Court MH, Krishnaswamy S, Hao Q et al. Evaluation of 3́-azido- 3́-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. 31(9), 1125-1133 (2003).
44. Sawyer MB, Innocenti F, Das S et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566-574 (2003).
45. Barbier O, Turgeon D, Girard C et al. 3́-azido-3́- deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 28(5), 497-502 (2000).
46. Picard N, Ratanasavanh D, Prémaud A, LeMeur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos. 33(1), 139-146 (2005).
47. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab. Dispos. 34(9), 1539-1545 (2006).
48. Kagaya H, Inoue K, Miura M et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(3), 279-288 (2007).
49. Lévesque E, Delage R, Benoit-Biancamano MO et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81(3), 392-400 (2007).
50. Sparks R, Ulrich CM, Bigler J et al. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res. 6(5), R488-R498 (2004).
51. Swanson C, Lorentzon M, Vandenput L et al. Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J. Clin. Endocrinol. Metab. 92(9), 3697-3704 (2007).
52. Thibaudeau J, Lépine J, Tojcic J et al. Characterization of common ugt1a8, ugt1a9, and ugt2b7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66(1), 125-133 (2006).
53. Blevins-Primeau AS, Sun D, Chen G et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 69(5), 1892-1900 (2009).
54. Wang H, Yuan L, Zeng S. Characterizing the effect of UDP- glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem. Pharmacol. 82(11), 1757-1763 (2011).
55. Takekuma Y, Takenaka T, Kiyokawa M et al. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J. Pharm. Pharm. Sci. 9(1), 101-112 (2006).
56. Takekuma Y, Takenaka T, Kiyokawa M et al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol. Pharm. Bull. 30(3), 537-542 (2007).
57. Hirota T, Ieiri I, Takane H et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos. 31(5), 677-680 (2003).
58. Honda M, Toyoda W, Shimizu T et al. Ugt2b73 did not affect the pharmacokinetics of R-and S-carvedilol in healthy Japanese. Drug Metab. Pharmacokinet. 22(5), 382-386 (2007).
59. Saeki M, Saito Y, Jinno H et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab. Dispos. 32(9), 1048-1054 (2004).
60. Lampe JW, Bigler J, Bush AC, Potter JD. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol. Biomarkers Prev. 9(3), 329-333 (2000).
61. Mehlotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur. J. Clin. Pharmacol. 63(1), 1-8 (2007).
62. Saito K, Moriya H, Sawaguchi T et al. Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin. Biochem. 39(3), 303-308 (2006).
63. Hwang MS, Lee SJ, Jeong HE, Lee S, Yoo MA, Shin JG. Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population. Drug Metab. Pharmacokinet. 25(4), 398-402 (2010).
64. Mojarrabi B, Butler R, Mackenzie PI. cDNA cloning and characterization of the human UDP glucuronosyltransferase, UGT1A3. Biochem. Biophys. Res. Commun. 225(3), 785-790 (1996).
65. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos. 26(6), 507-512 (1998).
66. Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J. Hum. Genet. 49(3), 123-128 (2004).
67. Chen Y, Chen S, Li X, Wang X, Zeng S. Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population. Drug Metab. Dispos. 34(9), 1462-1467 (2006).
68. Caillier B, Lépine J, Tojcic J et al. A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet. Genomics 17(7), 481-495 (2007).
69. Ieiri I, Nishimura C, Maeda K et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet. Genomics 21(8), 495-505 (2011).
70. Ehmer U, Vogel A, Schütte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39(4), 970-977 (2004).
71. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res. 64(3), 1190-1196 (2004).
72. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos. 33(5), 672-675 (2005).
73. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 8(4), R50 (2006).
74. Ghotbi R, Mannheimer B, Aklillu E et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol. 66(5), 465-474 (2010).
75. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 95(1-2), 1-8 (2011).
76. Erickson-Ridout KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet. Genomics 21(9), 539-551 (2011).
77. Saeki M, Saito Y, Jinno H et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab. Pharmacokinet. 20(2), 144-151 (2005).
78. Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. 307(1), 117-128 (2003).
79. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. 32(8), 775-778 (2004).
80. Thibaudeau J, Lépine J, Tojcic J et al. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66(1), 125-133 (2006).
81. Wang H, Yuan L, Zeng S. Characterizing the effect of UDP- glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselectiveglucuronidation of flurbiprofen. Biochem. Pharmacol. 82(11), 1757-1763 (2011).
82. Jinno H, Saeki M, Saito Y et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J. Pharmacol. Exp. Ther. 306(2), 688-693 (2003).
83. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5́-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin. Pharmacol. Toxicol. 103(2), 131-136 (2008).
84. Korprasertthaworn P, Udomuksorn W, Yoovathaworn K. Three novel single nucleotide polymorphisms of UGT1A9 in a Thai population. Drug Metab. Pharmacokinet. 24(5), 482-485 (2009).
85. Olson KC, Dellinger RW, Zhong Q et al. Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Drug Metab. Dispos. 37(10), 1999-2007 (2009).
86. Paoluzzi L, Singh AS, Price DK et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol. 44(8), 854-860 (2004).
87. Saeki M, Saito Y, Jinno H et al. Three novel single nucleotide polymorphisms in UGT1A9. Drug Metab. Pharmacokinet. 18(2), 146-149 (2003).